Orthofix Reports Q3 2026 Results and Revises Full-Year Guidance
FROM THE WIRE · BUSINESSWIRE.COM
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported financial results for the third quarter ended September 30, 2026, and revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance.…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishThe revised full-year guidance may affect investor expectations for the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Orthofix reported third quarter 2026 net sales of $207.9 million.
- 02Reported net sales increased 1%.
- 03The company revised its full-year 2026 net sales and non-GAAP adjusted EBITDA guidance.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets